| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | CHEMBL374350 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.021 | 0.9 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | 0.023 | 0.9 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.018 | 0.9 |